All Updates

All Updates

icon
Filter
Product updates
iRhythm wearable heart monitor increases AFib diagnoses by 52%
Preventive Healthcare
Sep 2, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Sep 2, 2024

iRhythm wearable heart monitor increases AFib diagnoses by 52%

Product updates

  • Zio XT, a wearable heart monitor developed by digital healthcare company iRhythm was tested in the GUARD-AF study. The study results showed that the Zio XT increased atrial fibrillation (AFib) diagnoses by 52% compared to standard care, with diagnosis rates of 5.0% vs. 3.3% over an average 15-month follow-up period.

  • The study involved nearly 12,000 patients aged 70 or above across the US and aimed to compare the device's effectiveness in detecting AFib against regular care. The Zio XT is a lighter, more discreet alternative to traditional Holter monitoring, allowing patients to wear the device for two weeks, enabling longer-term electrocardiogram monitoring.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.